ENTEROME Bioscience

Enterome is a medicine company developing drugs for chronic medical conditions relating to abnormalities of bacterial composition.

Enterome is a Paris-based private company with the most advanced technology and products in the emerging field of disease management of the human gut microbiome. Our company has been established in 2012 and has already raised a €7.5m series A with three private equity funds (Seventure, Omnes Capital & Lundbeckfond Ventures) and two strategic investors (Danone & Shire). Enterome develops science-based personalized medical tests and companion diagnostics based on profiling of the human gut microbiome with the goal to improve management of microbiome-related diseases, e.g., metabolic, gastrointestinal, and autoimmune. These chronic disorders depend on genetic susceptibility (polymorphisms of the human genome), but are also triggered by environmental factors where dysbiosis of the intestinal bacterial ecosystem (gut microbiome) is a major contributor. The method used by Enterome is based on mapping of total fecal bacterial gene content and functions, leading to the characterization of a personal metagenome (metagenotype) potentially for each individual. Each metagenotype is analyzed using proprietary algorithms (linking individual metagenotype to associated phenotypes) allowing proper evaluation of personal risk of each subject to develop a wide variety of pathological conditions. Enterome has built up a vertical R&D organization with in-depth expertise in clinical development: the Company has already prospectively enrolled more than 2000 patients in both the U.S. & EU, as well as having expertise in technological development (migration of large-scale sequencing towards commercial diagnostic platforms).